Isomorphic Labs, an AI-powered drug discovery company spun out of Alphabet Inc.’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new round of funding, according to people familiar with the plan.
Isomorphic Labs, an AI-powered drug discovery company spun out of Alphabet Inc.’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new round of funding, according to people familiar with the plan.